All In Biotech

Drug Trial Radar · NCT06754605

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (SCTV02) in Healthy Adults ≥18 Years of Age

Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Feb 6, 2025

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Jan 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, placebo-controlled Phase 1/2 clinical trial to evaluate the safety, tolerability and immunogenicity of recombinant respiratory syncytial virus in participants aged 18 years and older.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • SCTV02Biological

    Participants will receive a singe dose of SCTV02 on Day 0.

  • PlaceboBiological

    Participants will receive a singe dose of Placebo on Day 0.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of solicited adverse events within 7 days post study vaccination.Time frame: Day o to Day 7
  2. Geometric mean titer (GMT) of neutralizing antibodies (nAb) against RSV-A and RSV-B subtypes 30 days post vaccinationTime frame: Day 30

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hebei Zhongshiyou Central Hospital

    Langfang, Hebei, China · Recruiting

  • Luzhou Center for Disease Control and Prevention

    Luzhou, Sichuan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.